WCLC 2022 | Results of CeLEBrATE: carboplatin, etoposide, bevacizumab + atezolizumab ES-SCLC

Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, talks on the results of the multicenter Phase II CeLEBrATE trial (NCT04730999) investigating carboplatin, etoposide, bevacizumab and atezolizumab in patients with extensive-stage small cell lung cancer (ES-SCLC), which will be released in the second half of 2023. The primary endpoint is 1-year overall-survival (OS). This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.